Climb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at Baird R W

Key Points

• Climb Bio has been upgraded to a "strong-buy" rating by analysts at Baird R W, indicating increased optimism about the company's future performance.
• The stock is currently trading at $1.90, with a twelve-month low of $1.05 and a high of $8.79, reflecting significant volatility in its market value.
• Climb Bio reported an earnings per share (EPS) of ($0.13) for the last quarter, outperforming the consensus estimate, which suggests positive momentum in its financial performance.

Climb Bio (NASDAQ:CLYM - Get Free Report) was upgraded by investment analysts at Baird R W to a "strong-buy" rating in a research note issued on Friday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on CLYM. Oppenheimer began coverage on Climb Bio in a report on Friday, June 6th. They set an "outperform" rating and a $10.00 price objective for the company. Robert W. Baird started coverage on shares of Climb Bio in a report on Friday. They issued an "outperform" rating and a $9.00 price target on the stock. Finally, BTIG Research began coverage on shares of Climb Bio in a report on Thursday, May 22nd. They set a "buy" rating for the company. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $9.00.

Climb Bio Trading Up 10.5%

Shares of CLYM opened at $1.90 on Friday. Climb Bio has a twelve month low of $1.05 and a twelve month high of $8.79. The company has a market cap of $128.74 million, a P/E ratio of -2.71 and a beta of -0.11. The company's fifty day simple moving average is $1.41 and its 200-day simple moving average is $1.37.

Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. Analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Climb Bio

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new position in shares of Climb Bio during the first quarter valued at approximately $79,000. Peapod Lane Capital LLC bought a new position in Climb Bio in the first quarter worth approximately $676,000. TD Asset Management Inc bought a new position in Climb Bio in the first quarter worth approximately $109,000. XTX Topco Ltd bought a new stake in Climb Bio during the 1st quarter valued at $34,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Climb Bio during the 1st quarter valued at $86,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.